Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gruppo Italiano Malattie EMatologiche dell'Adulto
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed with Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (pre-PMF, overt-PMF) and post-ET/post-PV Myelofibrosis (MF), (i.e. Philadelphia chromosome negative myeloproliferative neoplasm (MPN)) according to 2016 WHO classification.
Known IPSS/IPSET/DIPSS risk score category at time of initial diagnosis of PV, ET and PMF, respectively.
Initial diagnosis of MPN within one year before date of registration.
Having a full baseline PRO Evaluation completed.
Adult patients (≥ 18 years old).
Written informed consent provided.
You may not be if
Having any kind of psychiatric disorder or major cognitive dysfunction problems hampering a self-reported evaluation.
Not able to read and understand local language (i.e. Italian).
Clareo Health | Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
